Gout

The Urate-Lowering Therapy to Acute Treatment Ratio (ULTrA) was linked to fewer gout-related hospital admissions.

Infusion reaction rates and serum level lowering were similar between 120-minute and 60-minute infusion cohorts in the phase 4 AGILE study.

Troum discussed positive efficacy and safety findings from the phase 4 AGILE study.

People that reported only some or none of their flares had almost twice the rate of gout flares in the last year than those reporting all of their flares.

SGLT-2 inhibitors had more protective effects than GLP-1 receptor agonists or DPP-4 inhibitors in this population.

The treatment did seem to blunt the glycemic response and influence some inflammatory cytokines.

Adherence to a preventative, favorable lifestyle significantly reduced CVD risk in participants with high and low genetic risk.

The analysis of NHANES data revealed an inverse association between dietary vitamin C intake and gout risk.

A comprehensive model of clinical and radiomic features was more accurate in distinguishing flares than either model alone.

Remission according to the simplified definition correlated with the 2016 preliminary gout remission definition and GIS score improvements.

Compared with participants who gained weight or who weight remained stable, the risk of developing gout fell with increased weight loss over 1 year.

This clinical quiz, our last in a series of 4, focuses on recommendations for special populations and long-term management from the 2020 ACR gout guidelines.

Higher Life’s Essential 8 score was associated with higher CVH scores in US adults.

Younger people and people without European origin were less likely to adhere to urate-lowering therapy.

There were no differences in the treatment effect of ertugliflozin on gout-related outcomes in subgroups based on eric acid quintile or other baseline characteristics.

Nehad Soloman, MD, FACR; Andrew Sharobeem, DO, FACR, and Sunil Patel, MD, explore the nephrologist's vital role in gout diagnosis, treatment options for gout patients with chronic kidney disease, and strategies for managing refractory gout and its associated challenges.

The increase will largely be driven by population growth and aging.

Patients also experienced a substantial decrease in systolic blood pressure and diastolic blood pressure.

This clinical quiz, our third in a series of 4, focuses on recommendations for lifestyle and comorbidity management from the 2020 ACR guidelines.

In general, current drinkers had a higher risk than never drinkers among men but not women.

Nehad Soloman, MD, FACR; Andrew Sharobeem, DO, FACR, and Sunil Patel, MD, explore the nephrologist's vital role in gout diagnosis, treatment options for gout patients with chronic kidney disease, and strategies for managing refractory gout and its associated challenges.

The rheumatology month in review emphasize's bimekizumab's efficacy in treating PsA and new risk factors and mitigators for developing gout or hyperuricemia.

Investigators identified 6 themes during semistructed interviews that contributed to and described the experience of people with gout.

Researchers identified 2 genes associated with increased risk and 3 associated with decreased risk.

This clinical quiz, our second in a series of 4, focuses on recommendations for management of gout flares from the 2020 ACR guidelines.